Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Starling Oncology, Inc.

Starling Oncology, Inc. (STLN) Stock Overview

Explore Starling Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.

STLN●NASDAQ
HealthcareMedical - Care Facilities
$4.34
$0.34(8.50%)
U.S. Market opens in 1h 15m

Starling Oncology, Inc. (STLN)

Meyka AI Score

Z

Key Financials

Market Cap433.9M
P/E Ratio-14.86
EPS (TTM)$-0.31
ROE1.51%
Fundamental Analysis

AI Price Forecasts

1 Month$6.82
3 Months$2.52
1 Year Target$7.84

STLN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Starling Oncology, Inc. (NASDAQ: STLN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Starling Oncology, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of STLN on the NASDAQ shows an RSI of 34.06, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $7.84 for the NASDAQ listing.

Key metrics behind Starling Oncology, Inc.'s NASDAQ-traded stock include a P/E ratio of -14.86 and a market capitalization of 433.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of STLN on the NASDAQ.

Price Performance (NASDAQ: STLN)

1-Day Change
8.50%
5-Day Change
-36.92%
1-Month Change
-34.54%
3-Month Change
-29.55%
6-Month Change
8.50%
Year-to-Date (YTD) Change
21.91%
1-Year Change
31.12%
3-Year Change
75.71%
5-Year Change
-56.29%
All-Time (Max) Change
-55.26%

Contact Information

https://www.starlingoncology.com
NaN
18000 Studebaker Road, Suite 800, Cerritos, CA, 90703

Company Facts

6,410 Employees
IPO DateAug 4, 2026
CountryUS
Actively Trading

Frequently Asked Questions